EVASTEM

Evastem is a French biotechnology company specializing in the development of regenerative therapies based on extracellular vesicles (EVs) derived from stem cells. The company utilizes a proprietary platform to produce high-purity EVs from human induced pluripotent stem cells (iPSCs), primarily targeting cardiovascular diseases such as heart failure. By leveraging the paracrine signaling properties of stem cells, Evastem's approach aims to promote tissue repair and reduce inflammation without the safety concerns associated with direct cell transplantation. The company's "off-the-shelf" therapeutic strategy is designed to be scalable and standardized for clinical use. Evastem is a spin-off from the CNRS and Université Paris Cité, building on extensive research in nanomedicine and cell biology.